| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/02/2001 | EP1095159A1 Bone morphogenic protein |
| 05/02/2001 | EP1095154A2 Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) |
| 05/02/2001 | EP1095143A2 Method for diagnosis and treatment of haemophilia a patients with an inhibitor |
| 05/02/2001 | EP1095139A2 Secreted proteins |
| 05/02/2001 | EP1095136A1 Cells and animals deficient in protein kinase c epsilon |
| 05/02/2001 | EP1095134A1 Method to prepare c-terminal modified peptides |
| 05/02/2001 | EP1095062A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 05/02/2001 | EP1095057A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 05/02/2001 | EP1095044A1 Piperazynil pyrimidine dione compounds selective for adrenoceptors |
| 05/02/2001 | EP1095040A1 New benzoxazoles with pde-inhibiting activity |
| 05/02/2001 | EP1095039A2 New pharmaceutically active compounds |
| 05/02/2001 | EP1095025A2 Benzimidazoles, production thereof and use thereof as medicaments |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095018A1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 05/02/2001 | EP1095016A1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095015A2 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 05/02/2001 | EP1095007A1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1094840A1 Use of texaphyrins in macrophage-mediated disease |
| 05/02/2001 | EP1094837A2 Porcine circovirus and parvovirus vaccine |
| 05/02/2001 | EP1094836A2 Methods of raising animals for meat production |
| 05/02/2001 | EP1094834A1 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| 05/02/2001 | EP1094832A1 Therapeutic use of uncoupling protein-hhfcw60 |
| 05/02/2001 | EP1094831A1 Compositions and methods for in vitro fertilization |
| 05/02/2001 | EP1094829A2 Methods for accelerating bone and cartilage growth and repair |
| 05/02/2001 | EP1094828A1 Use of neglected target tissue antigens in modulation of immune responses |
| 05/02/2001 | EP1094826A1 Novel therapeutic agents that modulate alpha-1a adrenergic receptors |
| 05/02/2001 | EP1094824A1 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 05/02/2001 | EP1094817A1 Compositions comprising gaba analogs and caffeine |
| 05/02/2001 | EP1094816A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/02/2001 | EP1094815A1 Farnesyl protein transferase inhibitors for treating arthropathies |
| 05/02/2001 | EP1094814A2 Methods and compositions for increasing penetration of hiv protease inhibitors |
| 05/02/2001 | EP1094813A2 Use of piperine for treating skin pigmentation disorders |
| 05/02/2001 | EP1094812A1 Angiogenesis inhibitors |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 05/02/2001 | EP1094807A1 Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies |
| 05/02/2001 | EP1094805A1 Substituted oxygen alicyclic compounds, including methods for synthesis thereof |
| 05/02/2001 | EP1094801A2 Poly(diallylamine)-based bile acid sequestrants |
| 05/02/2001 | EP1094798A2 INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 05/02/2001 | EP1094712A1 Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics |
| 05/02/2001 | EP1071329A4 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 05/02/2001 | EP0988304B1 Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv) |
| 05/02/2001 | EP0984959A4 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| 05/02/2001 | EP0983257A4 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| 05/02/2001 | EP0973392A4 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/02/2001 | EP0778820B1 Neurotrophic and antiproliferative compounds |
| 05/02/2001 | EP0769947B1 Indolinone compounds for the treatment of disease |
| 05/02/2001 | EP0750502B1 Use of phosphorus derivatives of alkaloids for treating endocrinopathies |
| 05/02/2001 | EP0743853B1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 05/02/2001 | CN1293674A Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient |
| 05/02/2001 | CN1293673A 1-(3-heteroarylpropyl-or-prop-2-enyl)-4-benzylpiperidines used as NMDA receptor antagonists |
| 05/02/2001 | CN1293669A Benzylpiperazingl-and benzylipeeridinyl ethanone derivatives, their preparation method and their use as dopamine D receptor antagonists |
| 05/02/2001 | CN1293666A Benzenesulfonamide-derivatives and their use as medicaments |
| 05/02/2001 | CN1293665A New compounds and their use as positive AMPA receptor modulators |
| 05/02/2001 | CN1293663A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamix acids as matrix metal-protease |
| 05/02/2001 | CN1293662A Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| 05/02/2001 | CN1293655A Bicyclo [2.2.1] heptanes and related compounds |
| 05/02/2001 | CN1293577A Iron-dextran compound for use as component in therapeutical composition for prophylaxis or treatment of iron-deficiency, process for producing said iron-dextran compound and use of said compound for p |
| 05/02/2001 | CN1293573A Methods of treating tardive dyskinesia and other movement disorders |
| 05/02/2001 | CN1293195A New polycyclicazaindole compound, its preparation method are medicine composition containing same |
| 05/02/2001 | CN1293192A New benzothiophene, benzofuran and indole compounds, preparation method therefor and medicine composition containing same |
| 05/02/2001 | CN1293066A Concatenated antidiotype monoclonic antibody vaccine for fish diseases |
| 05/02/2001 | CN1065246C Process for preparation of salt of clavulanic acid |
| 05/02/2001 | CN1065237C Cyclopentane-and-cyclo pentene-beta-amino acids |
| 05/02/2001 | CN1065139C Agent for promoting of phafocyte |
| 05/01/2001 | US6225486 Composition comprising mixture of free fatty acid conjugated linoleic acid isomers containing at least approximately 92 per cent trans 10, cis 12-octadecadienoic acid |
| 05/01/2001 | US6225351 For therapy of asthma, arthritis, and sepsis bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis, sepsis, septic shock, cachexia, acquire immuno deficiency syndrome (aids) |
| 05/01/2001 | US6225347 For lowering blood pressure, inhibiting platelet aggregation, for luteolytic effect, healing ulcer, inhibiting gastric acid secretion, as cytoprotective agent |
| 05/01/2001 | US6225345 Azahexane derivatives as substrate isosters of retroviral asparate proteases |
| 05/01/2001 | US6225339 Terpenoid lactone compounds and their production process |
| 05/01/2001 | US6225335 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease |
| 05/01/2001 | US6225328 Adamantyl-substituted retinoids and pharmaceutical/cosmetic compositions comprised thereof |
| 05/01/2001 | US6225326 Administering insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor for therapy to reduce side effect for diabetic patient |
| 05/01/2001 | US6225325 Administering n-substituted-1,5-dideoxy-1,5-imino-d-glucitol or galactitol for prophylaxis, therapy, reducing, or reversing multidrug resistance in patient undergoing therapy with chemotherapeutic agent |
| 05/01/2001 | US6225320 Treatment of pain, inflammation, migraine, emesis and posttherpetic neuralgia |
| 05/01/2001 | US6225315 Administering a cgmp pde inhibitor. |
| 05/01/2001 | US6225312 Piperazine and piperidine compounds |
| 05/01/2001 | US6225307 Caprolactam-phenyl phenylcarbamate |
| 05/01/2001 | US6225302 Amidino protease inhibitors |
| 05/01/2001 | US6225292 Inhibitors of DNA immunostimulatory sequence activity |
| 05/01/2001 | US6225287 Crystalline forms |
| 05/01/2001 | US6225284 Somatostatin peptides |
| 05/01/2001 | US6224901 Method for delivering beneficial compositions to hair follicles |
| 05/01/2001 | US6224875 Tanacetum parthenium extract and method of obtaining same |
| 05/01/2001 | US6224869 Isolated polypeptide |
| 05/01/2001 | US6224850 Antiwrinkle cosmetic/pharmaceutical compositions comprising iridaceae extracts |
| 05/01/2001 | US6224849 Alkylaminobenzothiazole and-benzoxazole derivatives |
| 05/01/2001 | CA2001265C Analogs of peptidase substrates |
| 05/01/2001 | CA2001264C 3.beta.,17.beta.-hydroxy-substituted steroids and related steroidal compounds |
| 05/01/2001 | CA1341219C Site specific mutagenesis in alpha-1-antitrypsin |
| 04/26/2001 | WO2001029564A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 04/26/2001 | WO2001029269A2 Gene expression profiling of inflammatory bowel disease |
| 04/26/2001 | WO2001029234A2 Self-cleaving rna sequences and their use for the control of protein synthesis |
| 04/26/2001 | WO2001029233A2 Chimeric immunogenic compositions and nucleic acids encoding them |
| 04/26/2001 | WO2001029219A1 Human cub-domain-containing protein and gene encoding the same |
| 04/26/2001 | WO2001029213A1 Human sit4 associated proteins like (sapl) proteins and encoding genes; uses thereof |
| 04/26/2001 | WO2001029209A1 Preparation of cellular components that are substantially free of chromosomal dna |
| 04/26/2001 | WO2001029198A1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 04/26/2001 | WO2001029178A2 Epo primary response gene 1, eprg1 |
| 04/26/2001 | WO2001029070A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |